Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	27.85	18.91	34.1	32.4	12.59	36.83
Short-Term Investments	271.56	169.35	73.53	50.57	107.92	-
Cash & Short-Term Investments	299.41	188.26	107.62	82.97	120.51	36.83
Cash Growth	53.60%	74.93%	29.71%	-31.15%	227.21%	-18.16%
Other Receivables	1.8	0.99	0.53	0.49	-	-
Receivables	1.8	0.99	0.53	0.49	-	-
Prepaid Expenses	3.58	1.26	0.94	3.62	0.8	0.89
Other Current Assets	1.01	1.15	0.34	0.47	1.31	0.24
Total Current Assets	305.8	191.66	109.43	87.55	122.62	37.96
Property, Plant & Equipment	0.81	0.86	1.23	1.56	0.19	0.18
Other Long-Term Assets	4.2	0.93	0.24	0.3	0.21	0.33
Total Assets	310.81	193.44	110.9	89.4	123.02	38.48

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.51	3.91	3.41	1.81	2.86	2.85
Accrued Expenses	6.02	5.53	6.81	3.71	3.52	3.81
Current Portion of Long-Term Debt	-	-	-	-	7	5.95
Current Portion of Leases	0.34	0.31	0.29	0.31	0.03	0.12
Total Current Liabilities	7.87	9.75	10.51	5.82	13.4	12.72
Long-Term Debt	-	-	-	-	2.15	8.65
Long-Term Leases	0.19	0.45	0.75	1.03	0	0.02
Other Long-Term Liabilities	-	-	-	-	0	-
Total Liabilities	8.06	10.2	11.26	6.86	15.56	21.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.14	0.13	0.09	0.07	0.06	0.03
Additional Paid-In Capital	686.36	512.77	386.53	321.64	317.59	197.96
Retained Earnings	-382.25	-329.8	-287.05	-239.13	-210.07	-180.92
Comprehensive Income & Other	-1.5	0.15	0.06	-0.03	-0.12	-
Total Common Equity	302.76	183.24	99.64	82.55	107.46	17.08
Shareholders' Equity	302.76	183.24	99.64	82.55	107.46	17.08
Total Liabilities & Equity	310.81	193.44	110.9	89.4	123.02	38.48

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.53	0.75	1.03	1.34	9.18	14.74
Net Cash (Debt)	298.88	187.51	106.59	81.63	111.33	22.09
Net Cash Growth	53.98%	75.91%	30.57%	-26.68%	404.06%	-28.27%
Net Cash Per Share	1.97	1.39	1.05	0.82	1.72	0.97
Filing Date Shares Outstanding	142.53	128.4	96.68	68.96	60.05	30.81
Total Common Shares Outstanding	142.53	128.31	93.6	68.28	59.94	28.51
Working Capital	297.93	181.91	98.92	81.72	109.22	25.23
Book Value Per Share	2.12	1.43	1.06	1.21	1.79	0.60
Tangible Book Value	302.76	183.24	99.64	82.55	107.46	17.08
Tangible Book Value Per Share	2.12	1.43	1.06	1.21	1.79	0.60
Machinery	-	0.51	0.35	0.3	0.21	0.11
Construction In Progress	-	0	0.01	0.02	0.05	-
Leasehold Improvements	-	0.03	0.03	0.03	0.13	0.13

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 9, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 13, 2026

Data Sources Report a data error